Read by QxMD icon Read

Radioiodine treatment

Saima Riaz, Humayun Bashir, Aamna Hassan, Sajid Mushtaq, Arif Jamshed, Ahmad Murtaza
We report an aggressive papillary thyroid carcinoma (PTC) with focal undifferentiated component in a 32-year-old female. She had limited disease confined within the thyroid gland at diagnosis. Within 12 months of thyroidectomy and radioiodine ablation, thyroglobulin (Tg) levels were elevated. Second radioiodine ablative dose was given, however, stimulated Tg levels showed an upward trend with negative iodine scan within 12 months. An 18F fludeoxyglucose-avid solitary pulmonary nodule that was detected on positron emission tomography/computed tomography scan was resected followed by empiric radioiodine therapy...
October 5, 2016: Molecular Imaging and Radionuclide Therapy
Yetunde A Onimode, John E Ejeh, Akintunde T Orunmuyi
OBJECTIVE: Radioactive iodine therapy (RAIT) is established as an efficient means of treating toxic goiter (TG) globally. The field of nuclear medicine (NM) still appears novel to many Nigerian clinicians and patients. A culturally embedded dread of radiation may raise ethical and moral concerns about potential adverse effects in the wake of RAIT in our setting. An adverse drug reaction may be described as "a response to a drug which is noxious and unintended, and which occurs at doses normally used in man"...
October 5, 2016: Molecular Imaging and Radionuclide Therapy
Javier López-Gómez, Ma Alejandra Salazar-Álvarez, Martin Granados-Garcia
INTRODUCTION: Thyroglosal duct cyst is a common anomaly with an incidence of 7% in adults, the rate of carcinoma in TGDC is 0.7-1.6%, and are extremely rare those originated in the hyoid bone. PRESENTATION OF CASE: A 60 years old male patient, had a hard mass in the anterior neck. CT revealed a hyoid tumor. Hyoid bone resection was performed, the pathological report show a conventional papillary carcinoma in bone tissue. We rule out primary tumor in thyroid gland...
September 29, 2016: International Journal of Surgery Case Reports
Friedhelm Raue, Karin Frank-Raue
Thyroid cancer is the most common endocrine malignancy. Differentiated thyroid cancer (DTC) with the two subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), is the most frequent subtype of thyroid cancer; more rare subtypes are medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC). The incidence of DTC has increased rapidly in recent years due to the more frequent use of imaging methods such as ultrasound of the neck and fine-needle aspiration (FNA) of thyroid nodules...
October 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Pawel Kawalec, Iwona Malinowska-Lipień, Tomasz Brzostek, Maria Kózka
Thyroid carcinoma is the most prevalent endocrine malignancy, with an increasing incidence over the past decades. Treatment of differentiated thyroid cancer consists of surgery followed by radioactive iodine (RAI) ablation of the thyroid remnant, and TSH suppression. Among new therapeutic solutions for patients with advanced RR-DTC stage, the most promising seem to be sorafenib and lenvatinib, up to now considered to be orphan drugs. Areas covered: We performed a systematic review of medical databases to collect all eligible clinical trials referring to the topic of our analysis...
October 13, 2016: Expert Review of Anticancer Therapy
Petr Vlček, Dana Nováková
Incidence of differentiated thyroid carcinomas, especially papillary carcinomas, in recent decades worldwide increase. This is especially the detection of small tumor sizes up to two centimeters. Causes of the increase of these cancers are either increased number of thyroid investigations, but also the actual increase of this disease. The subject of expert discussion on this topic is mainly assessment of the severity of newly diagnosed tumors, the choice of treatment strategy and choice of follow-up of patients...
2016: Vnitr̆ní Lékar̆ství
Zdeňka Límanová, Jan Jiskra
Cardiovascular system is essentially affected by thyroid hormones by way of their genomic and non-genomic effects. Untreated overt thyroid dysfunction is associated with higher cardiovascular risk. Although it has been studied more than 3 decades, in subclinical thyroid dysfunction the negative effect on cardiovascular system is much more controversial. Large meta-analyses within last 10 years have shown that subclinical hyperthyroidism is associated with higher cardiovascular risk than subclinical hypothyroidism...
2016: Vnitr̆ní Lékar̆ství
Rame Miftari, Valdete Topçiu, Adem Nura, Valdete Haxhibeqiri
PURPOSE: Papillary carcinoma is the most frequent type of thyroid cancer and was considered the most benign of all thyroid carcinomas, with a low risk of distant metastases. However, there are some variants of papillary thyroid carcinoma that have affinity to spread in many organs, such as: lymph nodes, lungs and bones. AIM: The aim of this study was presentation of a case with papillary carcinoma of the thyroid gland, very persistent and resistant in treatment with I 131...
July 27, 2016: Medical Archives
James Nagarajah, Mina Le, Jeffrey A Knauf, Giuseppe Ferrandino, Cristina Montero-Conde, Nagavarakishore Pillarsetty, Alexander Bolaender, Christopher Irwin, Gnana Prakasam Krishnamoorthy, Mahesh Saqcena, Steven M Larson, Alan L Ho, Venkatraman Seshan, Nobuya Ishii, Nancy Carrasco, Neal Rosen, Wolfgang A Weber, James A Fagin
Radioiodide (RAI) therapy of thyroid cancer exploits the relatively selective ability of thyroid cells to transport and accumulate iodide. Iodide uptake requires expression of critical genes that are involved in various steps of thyroid hormone biosynthesis. ERK signaling, which is markedly increased in thyroid cancer cells driven by oncogenic BRAF, represses the genetic program that enables iodide transport. Here, we determined that a critical threshold for inhibition of MAPK signaling is required to optimally restore expression of thyroid differentiation genes in thyroid cells and in mice with BrafV600E-induced thyroid cancer...
September 26, 2016: Journal of Clinical Investigation
P Anagnostis, K Boboridis, F Adamidou, M Kita
BACKGROUND/AIMS: The natural course of Graves' orbitopathy (GO) has been poorly documented. The aim of this review is to provide current knowledge regarding the natural course of mild GO, trying to address the issue of whether and to what extent it constitutes a chronic remitting or transient disease. METHODS: We systematically searched PubMed for English language publications until August 2016 under the following terms: "Graves' orbitopathy" OR "Graves' ophthalmopathy" OR "thyroid eye disease" AND "natural course" OR "natural history"...
September 23, 2016: Journal of Endocrinological Investigation
Mehran Pashnehsaz, Abbas Takavar, Sina Izadyar, Seyed Salman Zakariaee, Mahmoud Mahmoudi, Reza Paydar, Parham Geramifar
Iodine-131 (I-131) therapy is one of the conventional approaches in the treatment of patients with differentiated thyroid carcinoma (DTC). The radioiodine agents also accumulate in the other organs that cause pain and damage to the patients. Radioiodine therapy is associated with various gastrointestinal (GI) toxicities. In this study, GI side effects of the radioiodine therapy were investigated. GI toxicities of the radioiodine therapy were studied in 137 patients with histologically proven DTC in Jun-Nov 2014...
September 2016: World Journal of Nuclear Medicine
Jessica Hookham, Peter Truran, Amit Allahabadia, Sabapathy P Balasubramanian
BACKGROUND: Patients' perceptions and preferences influence the choice of radioiodine ablation (RIA) or surgery in the definitive management of Graves' disease. This study aimed to evaluate their concerns, experiences and satisfaction following definitive treatment. METHODS: A postal survey of patients who had treatment with surgery or RIA between January 2011 and June 2013 for Graves' disease was conducted. RESULTS: Of 214 patients, 136 (64%) responded...
September 20, 2016: Postgraduate Medical Journal
Katharina Mischler, Stefan Kneifel, Richard Cathomas
BACKGROUND: Metastatic differentiated thyroid cancer (DTC) is a rare disease that is in the first line treated with iodine-131 radioisotope therapy. Until recently, options were very limited in the case of progressive radioactive-iodine (RAI)-refractory disease. Based on new study results, tyrosine kinase inhibitors (TKIs) have attracted attention. The TKI sorafenib demonstrated significantly improved progression-free survival (PFS) in a phase III trial. Recent data from another phase III trial showed that the TKI lenvatinib achieved high response rates and a large improvement in PFS in metastatic RAI-refractory DTC patients in the first-line setting and after 1 prior line of TKI...
2016: Oncology Research and Treatment
W Xia, D Li, G Wang, J Ni, J Zhuang, M Ha, J Wang, Y Ye
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Currently, the clinical strategies available for the treatment of HCC remain insufficient for the poor prognosis. Sodium/iodide symporter (NIS)-based radioiodine therapy is proposed as a promising therapeutic strategy for the treatment of HCC. However, it is difficult for HCC cells to trap iodine for the lower expression of NIS. Small activating RNA (saRNA) is a newly identified small double-stranded RNA (dsRNA) that can induce endogenous gene expression by targeting promoter sequences...
September 9, 2016: Cancer Gene Therapy
Harun Ilhan, Mona Mustafa, Peter Bartenstein, Torsten Kuwert, Daniela Schmidt
: SPECT/CT detects radioiodine-positive cervical lymph node metastases (LNMs) of differentiated thyroid carcinoma (DTC) at the time of postsurgical radioablation (RA). Preliminary evidence indicates that the majority of LNMs are successfully treated by RA. The aim of this study was to confirm this evidence in a bicentric setting and to evaluate whether size is a predictor for successful elimination. PATIENTS AND METHODS: Since 01/2007 and 05/2008, respectively, SPECT/spiral-CT is performed routinely in all patients with DTC at RA in two University Clinics...
September 2, 2016: Nuklearmedizin. Nuclear Medicine
Fabricio Lopes da Fonseca, Patricia Kazue Yamanaka, Juliana Mika Kato, Suzana Matayoshi
BACKGROUND: Radioiodine therapy (RIT) is an established treatment for differentiated thyroid carcinomas and is widely used throughout the world, given the increasing incidence of this malignancy. Although serious adverse effects are infrequent, complications such as dry mouth, sialadenitis and dysphagia have been described. The involvement of the eyes and adnexa is not commonly discussed, despite dry eye, keratoconjunctivitis and lacrimal system obstruction (LSO) being reported, especially after high cumulative doses of radiopharmaceuticals...
August 26, 2016: Thyroid: Official Journal of the American Thyroid Association
M Zehtabian, N Dehghan, M Danaei Ghazanfarkhani, M Haghighatafshar, S Sina
The family members or friends of the patients undergoing treatment using radioiodine in nuclear medicine are inevitably exposed to ionization radiation. The purpose of this study is measurement of the dose received by the people taking care of the thyroid cancer patients treated by (131)I. For this purpose, the dose amounts received by 29 people accompanying patients were measured using thermoluminescence dosimeters. A badge containing three TLD-100 chips was given to each caregiver. The people were asked to wear the badges for 24 days, when they are taking care of the patients...
August 22, 2016: Radiation Protection Dosimetry
Piotr Szumowski, Małgorzata Mojsak, Saeid Abdelrazek, Monika Sykała, Anna Amelian-Fiłonowicz, Dorota Jurgilewicz, Janusz Myśliwiec
The therapeutic activity of (131)I administered to patients with Graves' disease can be calculated by means of Marinelli's formula. The thyroidal iodine uptake ((131)IUmax) needed for the calculation is usually determined with the use of (131)I. The purpose of the paper was to estimate (131)IUmax on the basis of technetium uptake in the thyroid at 20 min ((99m)TcU20min). Eighty patients suffering from Graves' disease were qualified for radioiodine therapy with measurement of fT4, fT3, thyroid-stimulating hormone and its receptor (TRAb)...
August 24, 2016: Endocrine
Bruce Robinson, Martin Schlumberger, Lori J Wirth, Corina E Dutcus, James Song, Matthew H Taylor, Sung-Bae Kim, Monika K Krzyzanowska, Jaume Capdevila, Steven I Sherman, Makoto Tahara
CONTEXT: Lenvatinib improved the progression-free survival (PFS) and overall response rate (ORR) of patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC) versus placebo in the Phase 3 Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid (SELECT). OBJECTIVE: To characterize tumor size changes with lenvatinib treatment. DESIGN: SELECT was a phase 3, randomized, double-blind, multicenter study. SETTING: In this clinical trial, tumor assessments of lenvatinib (n=261) and placebo-treated (n=131) patients were performed by independent radiologic review per Response Evaluation Criteria In Solid Tumors version 1...
August 22, 2016: Journal of Clinical Endocrinology and Metabolism
Doina Piciu, Claudiu Pestean, Elena Barbus, Maria Iulia Larg, Andra Piciu
BACKGROUND AND AIM: This study aimed at determining whether there is a risk regarding the development of second primary malignancies after patient exposure to the low and medium radioiodine activity used during the treatment of differentiated thyroid cancers (DTC). METHODS: Second primary malignancies that occurred after DTC were detected in 1,990 patients treated between 1970 and 2003. The mean long-term follow-up period was 182 months. RESULTS: Radioiodine I-131was administrated at a mean dose of 63...
2016: Clujul Medical (1957)
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"